Updated hourlyHourly refreshMon, Oct 26, 2026
Food & drink · Industrial
Farmer-founded, employee-owned beverage company ranks No. 34 among small and medium workplaces Tractor Beverage Company has been named to the 2026 Fortune Best Workplaces in Manufacturing & Production™ list, ranking No. 34 in the small and medium company category. Produced by Great Place To Work®, the list recognizes companies based on employees' feedback about their workplace experience. Tractor's
Oct 9 · 12:19·PR Newswire
Food & drink
Grand Opening on October 13 Marks 13th Location in Austin Metro
Grand Opening on October 13 Marks 13th Location in Austin Metro
Oct 9 · 12:00·GlobeNewswire
Food & drink
In a first, Beijing will host the Judging Week, where the competition's international panel of wine experts explore China's rich culture and wine terroir MACAO, Oct. 9, 2026 -- "Wynn Signature" – the exclusive lifestyle brand at Wynn – will unveil the full-year calendar and...
Oct 9 · 08:36·PR Newswire
AI · SaaS
Boca Raton, Florida Friday Oct 9, 2026 @ 4:00 AM Eastern —
NWB Finland Oy is continuing its planned U.S. rollout of AINA Natural Water, announcing that the Finnish premium water brand is coming soon to Amazon.
The upcoming Amazon availability represents another step in NWB Finland Oy’s strategy to introduce AINA Natural Water to U.S. consumers. The company previously announced that AINA would become available through OneLavi.com, marking the first opportunity for U.S. consumers to purchase the brand.
“Expanding to Amazon is an important next step for AINA in the United States,” said Marita Weiman, Quality Assurance Manager at NWB Finland Oy. “We want to make it easy for consumers to discover and purchase AINA while introducing them to what makes Northern Finnish water and our packaging approach different.”
AINA Natural Water originates in the Pudasjärvi region of Northern Finland, where groundwater is naturally filtered through layers of soil, sand and rock before being mechanically filtered and packaged.
The water contains approximately 32 mg/L of Total Dissolved Solids (TDS). Its naturally low mineral content contributes to a soft, neutral taste and clean finish with no aftertaste.
Premium Water Designed for Everyday Living
NWB Finland Oy has built AINA around the idea that premium water should be practical enough to become part of everyday life.
Instead of focusing on individual plastic bottles, AINA is offered in larger 5-liter and 10-liter bag-in-box formats designed for convenient use at home, at work and in other everyday settings. The sustainability-focused packaging uses substantially less plastic than comparable volumes packaged in traditional individual plastic bottles.
The approach combines three elements NWB Finland Oy believes can differentiate AINA in the U.S. market:
Northern Finland source
Naturally low mineral profile
Sustainability-Focused Packaging
AINA’s upcoming expansion to Amazon follows a series of steps by NWB Finland Oy to establish the brand in the United States. The company recently participated in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where AINA and its bag-in-box format were introduced to U.S. retail buyers.
“We are building AINA’s U.S. presence step by step,” Weiman said. “Amazon will significantly broaden the opportunity for consumers across the country to experience AINA Natural Water.”
The AINA Difference
Northern Finland Source - Originates in the Pudasjärvi region of Northern Finland, an area known for its forests, natural landscapes, and groundwater resources.
Naturally Filtered - Groundwater is naturally filtered through layers of soil, sand, and rock before being mechanically filtered and packaged.
Measured Purity - Contains approximately 32 mg/L of Total Dissolved Solids (TDS), contributing to a soft, clean taste profile.
Clean Taste Profile - Naturally low mineral content helps provide a balanced drinking experience with no aftertaste.
Naturally Low in Sodium - Contains only small amounts of sodium and dissolved minerals.
Sustainability-Focused Packaging - Bag-in-box packaging uses substantially less plastic than traditional bottled-water formats.
Additional details about Amazon availability will be announced when AINA Natural Water becomes available for purchase. For more information about AINA Natural Water, visit AINA Natural Water. To learn more about NWB Finland Oy, visit NWB Finland Oy.
About NWB Finland Oy
NWB Finland Oy is a Finland-based company focused on sustainable beverage packaging and natural water solutions. Headquartered in Pudasjärvi, Finland, the company was founded with a mission to develop environmentally responsible alternatives to traditional beverage packaging while delivering premium-quality products to consumers around the world.
Its flagship brand, AINA Natural Water, features naturally filtered groundwater sourced from Northern Finland, a region known for its pristine natural environment and abundant groundwater resources. The water is packaged in innovative bag-in-box formats designed to reduce plastic consumption while providing a convenient solution for households, businesses, hospitality venues, and events.
NWB Finland Oy's long-term vision is to make Northern Finland's natural groundwater available to consumers globally while continuing to invest in sustainable packaging solutions that support both consumer needs and environmental responsibility.
Oct 9 · 08:00·Newsworthy.ai
Retail · Food & drink
GFI India study finds strong consumer curiosity and acceptance for cultivated meat, but affordability, accessibility and trust will be critical to driving adoption. A new study by the Good Food Institute India (GFI India) finds that 94% of consumers express an intention to try cultivated meat, signalling strong consumer curiosity and openness towards a new […]
Oct 9 · 07:15·Webnewswire
AI · SaaS
Hong Kong, Oct 9, 2026 - Everest Medicines (1952.HK) announced the appointments of Lakshmi Srinivasan, PhD, as Senior Vice President, Head of Translational Medicine, and Brandon Coder, PhD, as Vice President, Translational Sciences & Discovery. Both executives are seasoned scientists in mRNA cancer vaccines, with deep experience spanning early discovery through clinical development and leadership roles in oncology vaccine research at Moderna and other leading biopharmaceutical companies.
The appointments further strengthen the Company’s global R&D capabilities in mRNA therapeutics, and support the continued advancement of its proprietary mRNA platform and pipeline. At Everest, they will drive clinical development of the Company’s mRNA programs and expand Everest’s presence in the United States, in line with the Company’s global mRNA R&D strategy, while working closely with the China R&D team.
The two scientists previously held leadership roles at Moderna, where they contributed to its mRNA cancer vaccine programs, including mRNA-4157/V940. Their experience spanning early-stage research through clinical development will support the advancement of Everest's proprietary mRNA platform and global clinical development programs. In August 2026, Moderna and Merck announced that mRNA-4157/V940 in combination with Keytruda met the primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS) in the Phase 3 INTerpath-001 study. The results represent the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy.
“We are very pleased to welcome Dr. Srinivasan and Dr. Coder to Everest Medicines as we continue to strengthen our global mRNA R&D capabilities,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Their deep experience in cancer vaccine research, translational medicine, and clinical development will be highly valuable as we advance our proprietary mRNA platform and broader pipeline. Their appointments reflect our continued commitment to investing in world-class talent and advancing our global mRNA strategy.”
Dr. Srinivasan is a seasoned immunologist with 20 years of experience advancing innovative immuno-oncology therapeutics from discovery through clinical development. Her expertise spans cancer vaccines, mRNA-LNP technologies, T-cell therapies, and translational development from preclinical research through clinical proof of concept. Prior to joining Everest Medicines, Dr. Srinivasan served as Executive Director and Head of Oncology Translational Medicine at Moderna Therapeutics from 2023 to 2025. She previously held leadership roles at Repertoire Immune Medicines, Neon Therapeutics, which was later acquired by BioNTech, and Sanofi Oncology. Dr. Srinivasan has played a key role in the clinical translation of personalized neoantigen vaccines and has authored multiple high-profile publications in the field. She served as corresponding author on Phase 1b studies of NEO-PV-01 published in Cell (2020) and Cancer Cell (2022), and co-authored publications on Moderna’s intismeran autogene (mRNA-4157/V940), including the Phase 1 KEYNOTE-603 study published in Cancer Discovery (2024) and the three-year follow-up of the randomized Phase 2b KEYNOTE-942 study published in JCO Oncology Advances (2026).
Dr. Coder brings more than 11 years of industry experience advancing T cell immunotherapies from discovery through investigational new drug (IND) submissions and early clinical proof of concept, with expertise in cancer vaccines, mRNA/LNP platform technology, and in vivo CAR therapies. Prior to joining Everest Medicines, Dr. Coder held scientific roles at Moderna from 2019 to 2025, most recently as Associate Scientific Director of Cancer Vaccine Research. He served as research and global pharmacology lead for intismeran autogene (mRNA-4157/V940), which reported positive results from the Phase 3 INTerpath-001 study in August 2026, becoming the first personalized neoantigen therapy and mRNA cancer therapy to achieve success in a Phase 3 clinical study. Dr. Coder also co-invented and led development of the shared-antigen discovery and vaccine design framework for mRNA-4359 and mRNA-4106. He contributed to nine IND submissions as a co-inventor, research lead, or core contributor, and co-authored the Phase 1 KEYNOTE-603 study of mRNA-4157/V940 published in Cancer Discovery (2024). Prior to joining Moderna, Dr. Coder served as Associate Director of Immuno-Oncology Research at Advaxis Immunotherapies, where he developed personalized and off-the-shelf cancer vaccines.
Leveraging its proprietary AI+mRNA platform, Everest Medicines is advancing multiple mRNA oncology therapeutic vaccine and in vivo CAR-T programs for oncology and autoimmune diseases. EVM16, a personalized mRNA therapeutic cancer vaccine, has completed its first-in-human clinical data readout, demonstrating a favorable safety and tolerability profile, robust immunogenicity and promising preliminary efficacy. Selected data were presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Following the Phase 1a study, EVM16 plans to initiate an investigator-initiated trial (IIT) Phase 1b study in Q4 2026 and launch new indication expansion cohorts for efficacy exploration. The company plans to submit an IND application to the U.S. Food and Drug Administration (FDA) in the first half of 2027. EVM14, an off-the-shelf tumor-associated antigen (TAA) mRNA cancer vaccine, received IND clearance from the U.S. FDA and IND approval from China’s National Medical Products Administration (NMPA) in 2025. The Phase 1 monotherapy dose-escalation study is expected to be completed in Q1 2027.EVM18, an in vivo CAR-T therapy, has initiated an IIT study in autoimmune diseases, with global IND filing underway. EVM15, an off-the-shelf immunomodulatory (IM) cancer vaccine, achieved clinical proof of concept in preclinical studies in 2025, with a clinical candidate subsequently selected. The Company plans to advance preparations for the Investigational New Drug (IND) application for EVM15 in 2026.
Oct 9 · 05:56·ACN Newswire
Healthcare · Automotive
FDA approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone1
First approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care
Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years2,3
Approval marks the twelfth indication for Tecentriq in the US
Basel, 9 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of stage III deficient DNA mismatch repair (dMMR) colon cancer, a type of tumour characterised by high mutation rates. This approval marks the twelfth indication for Tecentriq in the US.
“This approval provides a new adjuvant treatment option for people with stage III dMMR colon cancer who face a high risk of disease recurrence,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Tecentriq combined with chemotherapy has the potential to become the new standard of care as the first approved immunotherapy-based regimen for this setting.”
“Until now, the adjuvant standard of care for stage III colon cancer has not differed based on mismatch repair status,” said Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator for the Alliance ATOMIC trial. “This milestone represents an important therapeutic advance that leverages immunotherapy to target the specific biology of dMMR stage III colon cancer after surgical resection. By reducing the risk of disease recurrence or death by 50%, atezolizumab plus chemotherapy is a practice-changing regimen that can improve clinical outcomes of this group of patients living with colon cancer, one of the most common cancers and a leading cause of cancer-related death.”
The FDA approval is based on the landmark phase III ATOMIC study, recently published in The New England Journal of Medicine. ATOMIC demonstrated that adding Tecentriq to modified (m)FOLFOX6 chemotherapy reduced the risk of disease recurrence or death by 50%, compared to chemotherapy alone for people with stage III dMMR colon cancer, as determined by an immunohistochemistry test, such as the VENTANA® MMR RxDx Panel.1 The 36-month disease-free survival was 86% for Tecentriq combined with mFOLFOX6 compared with 76% in the mFOLFOX6 alone group. The safety profile was consistent with previous studies of Tecentriq and mFOLFOX6.1
Colon cancer remains one of the world's most common and deadliest tumours.4 Over one million people are diagnosed globally each year, and nearly 25% of all colon cancers are diagnosed at stage III.2-4 Despite surgery and chemotherapy, nearly 30% of stage III patients experience disease recurrence within five years.2,3 Approximately 15% of colon cancer patients present with dMMR or microsatellite instability-high (MSI-H) tumours, which indicate a higher mutation rate and thus have the potential to respond to immunotherapy.5
Roche is pursuing further regulatory filings for Tecentriq, including with the European Medicines Agency, to bring this immunotherapy-based adjuvant option to patients with dMMR colon cancer worldwide as soon as possible.
About the ATOMIC study
ATOMIC (A021502, NCT02912559) is a phase III, randomised, open-label, multicentre study investigating the addition of Tecentriq® (atezolizumab) to modified (m)FOLFOX6 chemotherapy (a combination of folinic acid, fluorouracil, and oxaliplatin) in patients with stage III colon cancer who have a deficiency in DNA mismatch repair (dMMR). The trial enrolled 712 patients. Participants were randomised 1:1 to receive either mFOLFOX6 plus Tecentriq for 12 cycles (six months) followed by Tecentriq monotherapy for 13 cycles (an additional six months), or mFOLFOX6 alone for 12 cycles. The primary endpoint is disease-free survival (DFS).
The global study in the US was sponsored by the US National Cancer Institute (NCI), part of the National Institutes of Health, and led by the Alliance for Clinical Trials in Oncology (Alliance) with participation from other NCI-funded National Clinical Trials Network (NCTN) groups. Genentech, a member of the Roche Group, provided support for the study through a Cooperative Research and Development Agreement between NCI and Genentech. The trial was led globally by Frank A. Sinicrope, MD, Professor of Oncology at the Mayo Clinic and US Principal Investigator within the Alliance. German participation in this major international academic collaboration was enabled through close cooperation between the Alliance and the AIO-Studien-gGmbH, in partnership with the AIO (Arbeitsgemeinschaft Internistische Onkologie) of the German Cancer Society (Deutsche Krebsgesellschaft, DKG), under the national leadership of Prof. Dr. Anke Reinacher-Schick (Ruhr-Universität Bochum). AIO-affiliated study sites enrolled patients during the later recruitment phase, ensuring access for eligible patients in Germany.
About Tecentriq® (atezolizumab)
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1, which is expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells.
Tecentriq has been approved for some of the most aggressive and difficult-to-treat forms of cancer, and is the first PD-(L)1 cancer immunotherapy available in both subcutaneous and intravenous formulations.
About Roche in oncology
For over 60 years, Roche has delivered transformative medicines and diagnostics, redefining the treatment of some of the most challenging cancers. Driven by a vision of a future where cancer can be cured, we focus our efforts on cancers with the highest societal impact and where we bring deep expertise, including breast, lung, and blood cancers, while pursuing breakthrough innovation in other areas of unmet need. Our pipeline features a diverse array of modalities, from small molecules and antibodies to next-generation ADCs and allogeneic CAR T-cell therapies. By advancing best-in-class precision medicine, pioneering novel combinations, and leveraging key technologies and partnerships, Roche tackles oncology's toughest challenges with the goal of delivering life-changing outcomes for people with cancer.
About Roche
Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.
Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.
Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Sinicrope F, et al. Atezolizumab plus FOLFOX for Stage III Mismatch Repair–Deficient Colon Cancer. N Engl J Med. 2026;394:1155-1166.
[2] Gonzalez B, et al. Analyzing recurrence in colorectal cancer: Is a five years follow-up enough? Annals of Oncology. 2024;35(1);11.
[3] Nors J et al. Incidence of Recurrence and Time to Recurrence in Stage I to III Colorectal Cancer: A Nationwide Danish Cohort Study. JAMA Oncology. 2024;10(1):54–62.
[4] World Health Organization. Cancer [Internet; cited 2026 October]. Available from: https://www.who.int/news-room/fact-sheets/detail/cancer.
[5] Boland CR, et al. Microsatellite Instability in Colorectal Cancer. Gastroenterology. 2010;138:2073–2087.
Roche Global Media Relations
Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com
Tristan Schmitz
Phone: +41 79 529 70 35Lorena Corfas
Phone: +41 79 568 24 95
Simon Goldsborough
Phone: +44 797 32 72 915Karsten Kleine
Phone: +41 79 461 86 83
Kirti Pandey
Phone: +41 79 398 38 53Yvette Petillon
Phone: +41 79 961 92 50
Irène Stephan
Phone: +41 79 377 83 75Albert Thottiyil
Phone: +41 79 775 66 12
Roche Investor Relations
Dr Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.comDr Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Attachment
Media&Investor Release FDA approval for Tecentriq Tecentriq Hybreza English
Oct 9 · 05:00·Roche
Food & drink
Akshayakalpa Organic, India’s leading certified organic dairy brand, has expanded its high-protein portfolio with the launch of High Protein Dahi, a protein-rich take on an everyday dairy staple, alongside High Protein Milk – Coffee and High Protein Milk – Kesar Elaichi. The new range brings together familiar dairy formats, taste and convenient nutrition to make […]
Oct 9 · 04:49·Webnewswire
Food & drink
Three-year partnership celebrates excellence, ambition and Botswana's remarkable development story through natural diamonds. High Resolution Images - Photo credit: Matt Borkowski / BFA.com LONDON and GABORONE, Botswana, Oct. 8, 2026 -- De Beers Group and the Government of the...
Oct 8 · 23:59·PR Newswire
AI · Retail
AI agents for retail grocery procurement are reaching scale — 100 million transactions this year. GSC opens in London, where 84 of every 100 makers are. VANCOUVER, BC and LONDON, Oct. 8, 2026 -- GreenCore Solutions Corp. (GSC) today introduces its 0–100 Agentic Density Scale...
Oct 8 · 23:15·PR Newswire
Food & drink
In the news release, Organic Valley Brings Cozy Fall Flavor to Coffee Cups Nationwide with a New Maple Cream Flavored Creamer, issued 08-Oct-2026 by Organic Valley over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with...
Oct 8 · 21:08·PR Newswire